Kelly M, Lloyd A, Furner V; Australasian Society for HIV Medicine. Conference.
Annu Conf Australas Soc HIV Med. 1994 Nov 3-6; 6: 265 (unnumbered poster).
Dept. Infectious Diseases PHH, Sydney.
BACKGROUND: Bactrim is established as the drug of choice for Pneumocystis Carinii Pneumonia (P.C.P.) prophylaxis. More than 25% of HIV infected patients are unable to tolerate Bactrim because of hypersensitivity. Bactrim desensitisation in previously hypersensitive patients can be dangerous with deaths from anaphylaxis and Stevens Johnson Syndrome being reported. Despite these concerns, an inpatient desensitisation protocol has been established (by A.C.) and is in regular use in our hospitals. AIM: To develop a safe, convenient and effective Bactrim desensitisation protocol for previously hypersensitive HIV infected patients that could be administered in the outpatient setting. METHODS: 25 HIV infected patients with CD4 cell counts less than 200/microliters with a past history of Bactrim hypersensitivity were recruited. Over a four day period increasing doses of Bactrim were administered according to the following schema: TABULAR DATA, SEE ABSTRACT VOLUME. Patients take one single strength tablet (400mg) daily thereafter. The initial three doses are given under medical supervision in the clinic and the following doses are given at home in the company of a carer. The patient is reviewed in the clinic daily for 3 further days. RESULTS/CONCLUSIONS: Based on our inpatient experience we anticipate a high success rate and patient acceptance. The results of our study will be discussed.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- CD4 Lymphocyte Count
- Desensitization, Immunologic
- HIV Infections
- HIV Seropositivity
- Humans
- Pneumonia, Pneumocystis
- Trimethoprim-Sulfamethoxazole Combination
Other ID:
UI: 102212374
From Meeting Abstracts